Skip to main content Skip to main content
Go to homepage

Grand Rounds: Redefining Collection of race and ethnicity data


By Nimisha Bajaj, MD, PhD, and Jenna Sahli, DO , Pediatric Palliative Care fellows, Akron Children's, Akron, OH

Palliative Care

Objectives (Educational Content) :

1. Identify diverse underlying diagnoses that may lead to symptoms which may improve with medical marijuana in pediatric palliative care. 2. Recognize potential indications for medical marijuana therapy in pediatric palliative care. 3. Describe the current legal status of medical marijuana in the United States. 4. Summarize two of the current research areas in the palliative care department at Akron Children’s Hospital.

Target Audience:

General pediatricians, family physicians, nurse practitioners, physician assistants, social workers, psychologists, and nurses.

Identified Gap:

Ethnicity and diversity is a key focus of Akron Children’s Hospital and this project identifies that when we focus on diversity we get to know the families we serve better and it helps families free more seen and share what they couldn’t before.

Estimated Time to Complete the Educational Activity:

1 hour(s)

Expiration Date for CE/CME Credit:


Method of Participation in the Learning Process:

The learner will view the presentation, successfully complete a post-test and complete an activity evaluation.

Evaluation Methods:

All learners must successfully complete a post-test, as well as an activity evaluation, to claim CE/CME credit.


Nimisha Bajaj, MD, PhD; Jenna Sahli, DO have indicated that they have no financial relationships with any ineligible companies.

Accreditation Statement:

Children’s Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.

CHMCA designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit TM.  Physicians should only claim the credit commensurate with the extent of their participation in the activity.


1. U.S. Congressional Research Service. The Evolution of Marijuana as a Controlled Substance and the Federal-State Policy Gap (R44782; April 7, 2022), by Lisa N. Sacco et al. Accessed November 27, 2022.

2. National Conference of State Legislatures. State Medical Cannabis Laws. United States, November 9, 2022. Accessed November 27, 2022. 

3. Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021;78(3):285-292. doi:10.1001/jamaneurol.2020.4607

4. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096. doi:10.1016/S0140-6736(18)30136-3

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.